title: [Successful low-dose TS-1 administration in an elderly colon cancer patient with liver metastasis].
abstract: An 85-year-old man, who had undergone right hemicolectomy and partial hepatectomy for caecum cancer with liver metastasis, was diagnosed with recurrent multiple liver metastasis 10 months after surgery. TS-1 administration at a dose of 80 mg/day induced grade 3 anorexia, and after complete recovery from the adverse reaction, it was converted to a low-dose TS-1 administration at 40 mg/day. This treatment reduced the diameter of the liver metastasis and was continued for ten months without any adverse reaction. Pharmacokinetic analysis in this patient on low-dose TS-1 showed that Cmax and AUC of 5-chloro-2,4-dihydroxypyridine (CDHP) were equivalent to the values reported in cancer patients with normal renal function receiving standard-dose administration. TS-1 therapy may provide a safe and effective alternative to chemotherapy for elderly patients with advanced colorectal carcinoma. Pharmacokinetic analysis could be useful for determining the ideal dose of TS-1.
authors: Dept. of Surgery, NTT West Osaka Hospital.
authors: Tadashi
authors: T
authors: Ohnishi
authors: Toshiyuki
authors: T
authors: Kanoh
authors: Yutaka
authors: Y
authors: Kimura
authors: Takashi
authors: T
authors: Iwazawa
authors: Takeshi
authors: T
authors: Tono
authors: Yoshiaki
authors: Y
authors: Nakano
authors: Koji
authors: K
authors: Yano
authors: Takushi
authors: T
authors: Monden
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000378:metabolism / Q000556:secondary; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000493:pharmacokinetics; D001063:Appendiceal Neoplasms / Q000556:secondary* / Q000601:surgery; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004338:Drug Combinations; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary* / Q000601:surgery; D008297:Male; D010094:Oxonic Acid / Q000008:administration & dosage* / Q000493:pharmacokinetics; D005641:Tegafur / Q000008:administration & dosage* / Q000493:pharmacokinetics
chemical_list: D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid